Glutamatergic Medications: Uses, Types, and Side Effects

Glutamatergic medications are drugs that alter the activity of glutamate, the brain’s main excitatory chemical messenger. They are already prescribed for conditions as different as Alzheimer’s disease, epilepsy, treatment-resistant depression, and alcohol dependence, and newer versions are in clinical trials for schizophrenia, chronic pain, and neurodevelopmental disorders. Because glutamate touches nearly every circuit in the brain, these drugs come in many flavors, each tuned to a specific receptor or mechanism, and each carrying a distinct side-effect profile that patients and clinicians need to weigh carefully.

Why Glutamate Is Such a Big Target

Glutamate is the primary excitatory neurotransmitter in the mammalian brain and also serves as a neuromodulator that shapes how synapses strengthen or weaken over time.¹ That dual role means it is involved in learning, memory, mood regulation, motor control, and sensory processing. Two broad families of receptors decode its signals: ionotropic receptors, which open ion channels quickly and drive fast electrical signaling, and metabotropic receptors, which trigger slower, longer-lasting chemical cascades inside the cell.

Glutamate signaling needs to stay within a narrow range. Too little activity and circuits cannot communicate properly; too much and neurons become overexcited and can die, a process called excitotoxicity. Astrocytes, a type of support cell in the brain, are responsible for mopping up excess glutamate from the space around neurons, and when that cleanup system fails, the surplus glutamate becomes toxic.² Most glutamatergic medications work by nudging this balance in one direction or the other: blocking excessive activation, enhancing weak signaling, or calming a specific receptor subtype that has gone haywire in a particular disease.

NMDA Receptor Antagonists

The best-known class of glutamatergic drugs targets the NMDA receptor, one of the ionotropic glutamate receptors. NMDA receptors play a key role in learning and synaptic plasticity, but they are also the main culprits in excitotoxic damage when they stay open too long.

Memantine for Alzheimer’s Disease

Memantine is a moderate-affinity, uncompetitive blocker of the NMDA receptor channel.³ In plain terms, it slips into the channel mainly when the receptor is being excessively stimulated and then leaves quickly enough that normal, healthy signaling can still get through.⁴ That selectivity is what makes memantine tolerable as a daily medication for moderate-to-severe Alzheimer’s: it damps down the background noise of excess glutamate activity without silencing the signals the brain still needs for day-to-day cognition. Memantine does not cure or reverse Alzheimer’s, but it can slow the worsening of symptoms and is frequently combined with cholinesterase inhibitors.

Ketamine and Esketamine for Depression

Ketamine, a more powerful NMDA blocker originally developed as an anesthetic, has found a second life in psychiatry. Across seven trials involving 147 ketamine-treated participants, the drug produced rapid antidepressant effects, with an odds ratio for response at 24 hours of about 10 compared to placebo.⁵ For people with treatment-resistant depression who have tried multiple medications without relief, that speed is unprecedented; most standard antidepressants take weeks to work. Esketamine, a nasal-spray formulation of one of ketamine’s mirror-image molecules, is now approved for treatment-resistant depression and is administered in supervised clinical settings. Intravenous ketamine clinics have also become widespread, though protocols and oversight vary.

The catch is that the antidepressant effect is transient, often fading within days to a couple of weeks, meaning repeated dosing is usually necessary. And the side effects during and shortly after an infusion can be intense: dissociation, perceptual distortions, impaired thinking, and experiences resembling both positive and negative symptoms of psychosis have all been documented in controlled studies of subanesthetic ketamine doses.⁶ These effects are brief in a clinical setting, but they are the reason esketamine must be given under medical supervision with a post-dose observation period.

Riluzole and Motor Neuron Disease

Riluzole was the first drug approved specifically for amyotrophic lateral sclerosis (ALS). Although the precise details of how it works are still being investigated, it is widely considered an antiglutamatergic agent because it reduces glutamate transmission in the central nervous system.⁷ In ALS, motor neurons are believed to suffer excitotoxic damage from excessive glutamate, and by dialing that down, riluzole modestly extends survival. The benefit is real but limited — on the order of a few months — and it does not restore lost motor function. Still, it remains a cornerstone of ALS treatment because few other drugs have shown even that level of benefit in clinical trials for this disease.

AMPA Receptor Drugs

The AMPA receptor is another ionotropic glutamate receptor and handles much of the brain’s fast excitatory signaling. Drugs targeting AMPA receptors can work in opposite directions depending on the goal.

Perampanel for Epilepsy

Perampanel is an AMPA receptor antagonist, meaning it blocks the receptor, and it is approved as an add-on treatment for certain types of seizures. The logic is straightforward: if excess excitation drives seizures, dampening AMPA receptor activity should help. It does, but it comes with a distinctive side-effect profile. In phase III trials, psychiatric side effects appeared in roughly 17–22% of patients on higher doses, compared with about 12% on placebo. Hostility and aggression events were especially notable, occurring in up to about 6% of patients at the highest dose versus under 1% for placebo.⁸ These rates were dose-dependent, and the events rarely led to hospitalization, but the hostility signal was prominent enough to earn a specific warning in prescribing information. Patients with epilepsy who do not have a psychiatric history tend to tolerate it better, and non-epilepsy participants in early trials showed psychiatric side-effect rates similar to placebo.

AMPAkines as Cognitive Enhancers

Moving in the opposite direction from perampanel, AMPAkines are positive allosteric modulators of AMPA receptors. Instead of blocking the receptor, they make it respond more efficiently when glutamate arrives, which can boost brain-derived neurotrophic factor (BDNF) levels and strengthen synaptic plasticity — the cellular basis of learning and memory.⁹ The appeal is that they preserve normal receptor timing rather than flooding the system, which theoretically reduces the risk of overstimulation.¹⁰ In animal models of brain injury, type II AMPAkines restored hippocampal function and improved memory even when administered weeks after the initial insult. Human trials have been limited so far, and no AMPAkine has yet been approved for clinical use, but this class is being explored for conditions ranging from cognitive decline after brain injury to respiratory depression and neurodegenerative disease.

Metabotropic Glutamate Receptor Modulators

Metabotropic glutamate receptors (mGluRs) work more slowly than their ionotropic cousins. Instead of opening an ion channel directly, they trigger intracellular signaling cascades that modulate how neurons respond over seconds to minutes. Different subtypes of mGluRs are distributed across different brain regions and cell types, making them attractive targets for fine-tuned drug development.

One area of active research is schizophrenia. A phase II trial demonstrated antipsychotic effects from an agonist of the mGluR2/mGluR3 subtypes, suggesting that boosting signaling at these receptors could provide an alternative to the dopamine-blocking drugs that have dominated schizophrenia treatment for decades.¹¹ On a related track, a different approach to schizophrenia has recently reached the market: xanomeline-trospium, the first approved drug that works through muscarinic receptor modulation rather than dopamine blockade, and it indirectly affects glutamate circuits as well.¹²

Another target, the mGluR5 receptor, has been explored in fragile X syndrome, the most common inherited cause of intellectual disability. In fragile X, mGluR5 signaling is thought to be overactive, and drugs that dampen it showed initial promise in animal models. Mavoglurant, an mGluR5 antagonist, was tested in proof-of-principle clinical studies for fragile X and also for L-dopa-induced involuntary movements in Parkinson’s disease.¹³ However, laboratory studies with a related compound found that chronic treatment led to acquired treatment resistance in fragile X model mice across multiple measures, including seizure susceptibility and cortical hyperexcitability.¹⁴ That tolerance problem has been a major hurdle, and large human trials of mGluR5 drugs for fragile X ultimately failed to meet their primary endpoints. Research continues with newer compounds and different dosing strategies, including drugs like MRZ-8456 that have shown rescue of key markers in animal models and completed a phase I clinical trial.¹⁵

Lamotrigine as a Glutamate-Modulating Mood Stabilizer

Lamotrigine is one of those drugs that defies easy classification. It is officially an antiepileptic, but it is widely prescribed as a mood stabilizer for bipolar disorder, particularly for preventing depressive episodes. Part of how it works involves blocking voltage-sensitive sodium channels on neurons, which in turn inhibits the release of glutamate.¹⁶ It is not a direct glutamate receptor blocker, but by reducing the amount of glutamate that gets released in the first place, it achieves a downstream effect on the glutamatergic system. Among mood stabilizers, lamotrigine stands out for being generally well tolerated and for having a distinct role in the depressive pole of bipolar illness, where options are more limited than for mania. The main safety concern is a rare but serious skin reaction (Stevens-Johnson syndrome), which is why the dose must be increased very slowly over weeks.

Glutamatergic Drugs in Alcohol Dependence

Chronic heavy drinking throws glutamate signaling out of balance. Alcohol suppresses glutamate activity while it is on board, and the brain compensates by upregulating the glutamate system. When someone abruptly stops drinking, that compensatory upregulation is suddenly unopposed, producing a surge of excitatory activity that contributes to withdrawal symptoms and can cause seizures or worse.¹⁷

Acamprosate is designed to calm this hyperglutamatergic state. Evidence at the molecular level suggests it works through both ionotropic NMDA and metabotropic mGluR5 receptors, along with changes in intracellular calcium signaling.¹⁸ One intriguing finding is that acamprosate works best in people who start with elevated glutamate levels. In studies measuring serum glutamate, responders had baseline levels around 32 micromolar, compared with about 23 micromolar in nonresponders. After treatment, glutamate dropped by nearly 10 micromolar in responders while barely changing in nonresponders — a pattern that replicated across two independent samples.¹⁹ This raises the possibility of using a simple blood test to predict who will benefit most from the drug, though such testing is not yet part of routine clinical practice.

D-Cycloserine and Exposure Therapy

D-cycloserine (DCS) is a partial agonist at the NMDA receptor, meaning it gently enhances the receptor’s activity without fully activating it.²⁰ Its most creative use is not as a standalone psychiatric medication but as a booster for psychotherapy. In exposure therapy for phobias and anxiety disorders, the patient gradually confronts feared stimuli until the fear response weakens — a process called extinction. NMDA receptors are involved in the learning that underlies extinction, so a small dose of DCS taken before or after a therapy session can speed that process up.

A meta-analysis combining animal and human data found that DCS enhanced fear extinction and exposure therapy, with gains generally maintained at follow-up. The drug worked best when given only a few times and timed close to therapy sessions, rather than taken daily.²¹ In a study of people with fear of heights, those who received DCS during virtual-reality exposure therapy showed significantly less fear at subsequent sessions, even when they no longer had the drug on board.²² The idea of a pill that makes therapy sessions more effective has obvious appeal, though clinical adoption has been slow, partly because the dosing and timing require coordination that is hard to implement in routine practice.

Side Effects Worth Knowing About

Because glutamate signaling is so widespread in the brain and body, side effects across this drug class tend to fall into a few recurring themes. Drugs that block glutamate receptors can produce cognitive dulling, sedation, and dissociative symptoms. Those that enhance glutamate activity risk overstimulation, anxiety, or seizures at high enough doses. But some risks are more specific.

Ketamine’s urinary tract effects deserve special attention. Recreational ketamine abuse has been linked to a roughly three- to four-fold increased risk of cystitis symptoms, including urinary pain, reduced bladder capacity, and in severe cases, kidney damage.²³ These complications are associated with chronic recreational use at high doses, not the intermittent low-dose infusions used in depression treatment, but they are a cautionary note for anyone using ketamine outside medical supervision.²⁴ Stopping ketamine use usually improves symptoms, but severe cases can require surgical intervention. Beyond bladder problems, persistent memory deficits and changes in thinking patterns have also been reported with heavy recreational use.²⁵

Perampanel’s behavioral side effects, discussed earlier, are a reminder that blocking excitatory transmission can affect mood and impulse control as well as seizure threshold. And for lamotrigine, the slow dose titration required to avoid serious skin reactions can frustrate patients and clinicians who want faster relief, but skipping that ramp-up period is genuinely dangerous.

The MSG Misconception

A question that comes up frequently when people learn about glutamate in the brain is whether eating glutamate-rich foods, especially those containing monosodium glutamate (MSG), could affect brain function. The short answer is that dietary glutamate does not meaningfully reach the brain. Almost none of the glutamate you swallow makes it from the gut into the bloodstream in the first place, and the blood-brain barrier prevents what little does enter the blood from crossing into brain tissue, except under extreme experimental conditions involving doses far beyond what anyone encounters in food.²⁶ Glutamate is, in pharmacological terms, “metabolically compartmentalized” — the body keeps it where it belongs.²⁷ This is why glutamatergic drugs have to be specifically designed to cross the blood-brain barrier or be delivered by injection or nasal spray. A plate of food seasoned with MSG is not doing that.

Measuring Glutamate in Living Patients

One of the challenges in developing glutamatergic drugs has been the difficulty of directly measuring glutamate activity in a living brain. You cannot draw blood and get a reliable picture of what glutamate is doing at specific synapses, because the brain keeps its glutamate pool tightly separated from the rest of the body. The workaround is magnetic resonance spectroscopy (MRS), a specialized type of brain scan that can detect neurotransmitter and metabolite concentrations in specific brain regions without requiring surgery or radioactive tracers.²⁸ MRS has enabled researchers to build models connecting brain glutamate levels to psychiatric symptoms and to track whether a drug is actually changing neurotransmitter concentrations as expected. The technique remains mostly a research tool, but it has real potential as a clinical biomarker: if you could scan a patient before prescribing and see whether their glutamate levels in a specific region were abnormally high or low, you could make a more informed choice about which glutamatergic drug might help.

The Gut-Brain Axis and Glutamate

Beyond the MSG question, there is growing interest in how glutamate signaling operates along the gut-brain axis. Glutamate receptors are not exclusive to the brain; they are also found in the gut, where they influence taste perception, the sensitivity of internal organs, and gut motility. Gut bacteria themselves can produce and consume glutamate, and researchers are investigating whether shifts in the gut microbiome might modulate glutamate signaling enough to affect mood and stress responses.²⁹ The work is still at an early stage, and nobody is yet prescribing probiotics as a glutamatergic intervention, but the finding that glutamate receptors along this axis may influence both local gut function and distant brain processes opens a new front for research. If alterations in gut glutamate transmission contribute to conditions like irritable bowel syndrome or anxiety, targeted gut-level glutamatergic therapies could eventually enter the picture.